Key Takeaways
- •Pinealon is a synthetic tripeptide, Glu-Asp-Arg or EDR. Three amino acids, no modified residues, no branching.
- •Despite the name it is not the pineal gland peptide. That is Epithalon (AEDG). Pinealon's assigned tissue in Khavinson's scheme is the central nervous system broadly, and the two are routinely confused.
- •The headline claim is unusual: that a three-residue peptide enters the nucleus and binds DNA at specific sequence motifs. Fedoreyeva et al. (2011) showed nuclear entry in HeLa cells and a measurable binding preference for CAG-containing sequences (PMID 22117547).
- •In a rat model of prenatal hyperhomocysteinemia, cerebellar neurons taken from the offspring of treated dams showed lower reactive oxygen species and fewer necrotic cells (PMID 22567179). That is the only animal study here.
- •A 2014 cell-culture paper reported stimulated serotonin expression, with a tryptophan hydroxylase binding site predicted by molecular docking rather than measured (PMID 24909721).
- •Almost none of this has been replicated outside Khavinson's group. The peptide bioregulator framework is a working hypothesis, not established biology, and Pinealon is for laboratory research only.
Summary
Pinealon is a three amino acid peptide, Glu-Asp-Arg, usually written EDR. It is not the pineal gland peptide despite the name: that one is Epithalon, and the two get mixed up constantly. Pinealon came out of Vladimir Khavinson's peptide bioregulator programme in St Petersburg, where it is assigned to the central nervous system rather than to any one gland.
The claim that makes it interesting is also the claim that makes it hard to accept. Khavinson's group reports that a peptide this short enters the cell nucleus and binds DNA at specific sequence motifs, acting as a kind of epigenetic switch. The best evidence for it is real: fluorescently labelled EDR does reach HeLa nuclei, and it binds CAG-containing sequences more strongly than other motifs, with a pattern that differs from other peptides in the same experiment.
What is missing is everything after that. No independent laboratory has reproduced the key results, the tryptophan hydroxylase binding site is a computational prediction rather than a measurement, and there is exactly one animal study. The mechanism is worth studying and is not yet established. It is supplied for laboratory research only.
Why This Guide Exists
Search for "pinealon" and you will find a strange gap. Dozens of comparison pages rank reasonably well for "pinealon vs semax" or "pinealon vs epithalon," yet the compound's own name barely shows up in the top results anywhere. That is backwards for a peptide with actual published literature behind it. This guide is our attempt to close that gap: what Pinealon (EDR) actually is, what the Khavinson group's published work reports, and where the evidence stops.
Pinealon is a synthetic tripeptide with the sequence glutamate, aspartate, arginine, shortened to EDR using single letter amino acid codes. It came out of the peptide bioregulator research program run by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology.
Published papers from that group describe EDR entering cell nuclei and interacting with specific DNA sequences, plus cellular readouts in central nervous system cell culture and one animal model. We are covering both here, along with the honest limitation that almost none of this work has been replicated outside the group that produced it.
Pinealon is available for laboratory research only.
What Pinealon Is
Start with the chemistry, since it is simple and often skipped over. Pinealon is glutamic acid, aspartic acid, and arginine linked in that order: Glu-Asp-Arg, or EDR. Three amino acids. No branching, no modified residues, nothing exotic. That size matters for a lot of what follows, because a tripeptide behaves very differently from a 30 or 40 residue peptide in terms of stability, membrane crossing, and how easily it gets degraded once it is in solution.
The compound sits inside a larger family Khavinson's group calls peptide bioregulators. Each one is a short peptide, usually two to four amino acids, matched conceptually to a tissue of origin. Epithalon (Ala-Glu-Asp-Gly, AEDG) is the pineal gland peptide. Cortagen targets cerebral cortex tissue. Vesugen is associated with vascular tissue. Pinealon's assigned tissue is the central nervous system broadly, not the pineal gland specifically, despite the name's obvious echo of "pineal." That naming choice trips people up. Epithalon is the pineal-derived one; Pinealon is the CNS-targeted one, and the two get confused in casual write-ups more often than you'd expect.
Where does the idea come from in the first place? Khavinson's rationale traces back to older work on tissue extracts, Epithalamin among them, a polypeptide preparation derived from bovine pineal tissue that was studied in Russian laboratories going back decades. The theory was that pineal and CNS tissue contain naturally occurring short peptides that carry some kind of regulatory signal specific to that tissue, and that synthesizing short fragments matching those sequences might reproduce part of that signalling without needing a crude tissue extract. Pinealon is one of several synthetic tripeptides built on that premise, positioned as a cleaner, better-defined alternative to whole-extract preparations like Epithalamin.
Whether that theoretical framework holds up is a separate question from whether the specific experimental findings on Pinealon are real and worth examining. We think they are worth examining. But it is fair to flag upfront that the "tissue-specific regulatory peptide" idea is Khavinson's interpretive lens on the data, not an independently established mechanism accepted broadly across peptide biology. Keep that separation in mind as we go through the actual findings.
Key Research Findings at a Glance
- Fedoreyeva et al. showed fluorescently labeled EDR penetrates into the nucleus of HeLa cells and binds specific DNA sequences with measurable specificity, using fluorescence quenching assays (PMID 22117547).
- In a rat model of prenatal hyperhomocysteinemia, cerebellar neurons from the offspring of treated dams showed reduced reactive oxygen species and necrotic cell counts (PMID 22567179).
- EDR increased serotonin expression in senescent brain cortex cell cultures, with molecular docking data suggesting a binding site in the tryptophan hydroxylase gene (PMID 24909721).
The Peptide Bioregulator Framework
Here is the hypothesis in plain terms. Khavinson's group proposes that ultrashort peptides, two to four amino acids, can enter a cell nucleus and physically interact with DNA at specific sequence motifs, functioning as a kind of epigenetic switch that turns certain genes up or down. This is a stronger and more specific claim than "peptides can affect gene expression somehow." It says these particular short sequences bind particular DNA regions and that binding has downstream transcriptional consequences.
That is a hypothesis, not settled biology. Short peptide to DNA interaction of this kind is not part of mainstream molecular biology curricula, and most gene regulation research focuses on transcription factors, which are considerably larger proteins with well-characterized DNA-binding domains. A three or four amino acid chain interacting sequence-specifically with double-stranded DNA is an unusual claim on its face. It is not impossible. Short peptide-nucleic acid interactions do exist in nature (certain antimicrobial peptides, some viral proteins use short motifs to engage nucleic acids), but the specificity and functional consequence Khavinson's group describes for compounds like EDR is a much bigger ask.
What supports it
The clearest piece comes from Fedoreyeva and colleagues. They used fluorescently labeled versions of several bioregulator peptides, EDR among them, and tracked their movement into HeLa cell nuclei under a microscope.
They then ran fluorescence quenching experiments to test whether the peptides bound labeled DNA oligonucleotides in vitro. Binding strength varied with the nucleotide sequence tested: EDR preferred CAG-containing sequences, and that preference differed from Epithalon's and from bronchogen's in the same experiment.
That is the strongest evidence for the sequence-specific part of the hypothesis, because different peptides picking out different motifs is hard to explain as an artefact. It does not prove a transcriptional consequence on its own, but it is a real biochemical observation rather than a claim.
Where it gets thin
The missing link is between nuclear DNA binding and the downstream readouts reported in cell cultures and animals.
The gene expression changes Khavinson's group reports, serotonin pathway genes and antioxidant response genes depending on the paper, are consistent with the DNA-binding hypothesis but do not establish it. Peptide present plus genes changed does not mean the peptide changed them by binding DNA, as opposed to by some signalling cascade it set off another way.
The docking study covered below is a computational prediction, not a biochemical demonstration of binding at that promoter. Treat the framework as a working hypothesis with interesting data behind it, not a proven mechanism.
The concentration-response argument
One earlier paper from the group, published in 2011, is worth calling out because it tests the genome-interaction claim directly rather than describing downstream readouts.
Khavinson, Ribakova, Kulebiakin and colleagues found that Pinealon reduced reactive oxygen species and necrotic cell death, concentration dependently, in three different cell types: cerebellar granule cells, neutrophils, and PC12 pheochromocytoma cells. They also tracked ERK 1/2 activation and cell cycle progression.
The interesting part is the shape of the curves. The ROS reduction saturated at low concentrations while cell cycle modulation kept scaling at higher ones. Two readouts with two different concentration-response curves suggests two mechanisms rather than one wearing two hats, and that is the argument the authors used for a direct genome interaction on top of the ROS-scavenging activity (PMID 21978084).
What the Published Research Reports
We reviewed the primary papers behind the claims most commonly repeated about Pinealon online, and it is worth being specific about which model system produced which finding, since a lot of secondary coverage blurs cell culture data into animal data into vague "studies show" language. Three papers carry most of the weight here.
The DNA Interaction Hypothesis
Fedoreyeva, Kireev, Khavinson and Vanyushin published the foundational nuclear-penetration paper in Biochemistry (Moscow) in 2011.
They worked in HeLa cells, a human cervical cancer line and not neuronal tissue, which is a detail some secondary coverage skips. Cells were incubated with fluorescein-labeled short peptides, EDR among them, and fluorescence accumulated in the cytoplasm, the nucleus and the nucleolus. That established that the peptides physically get inside the nucleus.
Separately, the team ran in vitro binding assays using fluorescence quenching, measuring how strongly each peptide interacted with different single and double stranded DNA oligonucleotide sequences.
The result: EDR, epithalon and testagen all preferred CAG-containing sequences, while bronchogen preferred CTG. The peptides also appeared able to tell methylated from unmethylated cytosine at CNG sites, which the authors flagged as potentially relevant to epigenetic regulation (PMID 22117547).
This is a HeLa cell and in vitro biochemistry paper. It says nothing directly about neurons and nothing about live animals. What it does establish, reasonably convincingly, is that this class of short peptide can enter nuclei and bind DNA with some sequence specificity. That is the base the rest of the framework builds on.
Is that enough to call it settled? No. One paper, one lab, one cell line, no independent replication we could locate in the broader literature. The finding is specific enough (measurable quenching constants, distinct binding patterns across different peptides) that it doesn't read like vague hand-waving, and the method (fluorescence quenching for nucleic acid binding) is a standard technique used elsewhere in biochemistry. Still, "used a standard technique" and "independently confirmed by another group" are different bars, and only the first one is cleared here.
The serotonin finding
The functional half of the hypothesis, that DNA binding actually drives the effects reported elsewhere, comes from Khavinson, Lin'kova, Tarnovskaya and colleagues in the Bulletin of Experimental Biology and Medicine, 2014.
Working in senescent brain cortex cell cultures, they found that EDR and a related peptide, Lys-Glu-Asp, increased serotonin expression. Using molecular docking, a computational method for predicting how a small molecule fits a target structure, they identified a CCTGCC sequence inside the tryptophan hydroxylase gene as a plausible complementary binding site (PMID 24909721). Tryptophan hydroxylase catalyses the rate-limiting step of serotonin synthesis.
The authors interpret this as epigenetic regulation of the serotonin synthesis pathway.
Two things worth flagging about that paper. First, "molecular docking suggests a binding site" is a prediction, not direct structural confirmation via something like crystallography or a gel shift assay. It is a reasonable first step, not a final answer. Second, senescent cell cultures are a specific and somewhat unusual model system; the serotonin finding is interesting but narrow, and it hasn't (to our knowledge) been extended to a broader gene panel to see how general the effect is.
The one animal study
The third major paper leaves cell culture. Arutjunyan, Kozina, Stvolinskiy, Bulygina, Mashkina and Khavinson published in the International Journal of Clinical and Experimental Medicine in 2012, examining Pinealon in pregnant rats with diet-induced hyperhomocysteinemia. That model raises homocysteine through excess dietary methionine and is used to study prenatal metabolic stress in the offspring.
The paper reports behavioural measures in the offspring, which this guide does not summarise, and cellular measures: reduced reactive oxygen species and fewer necrotic cells in cerebellum neurons taken from the offspring of treated dams (PMID 22567179).
The authors call the finding consistent with earlier in vitro data from the same research group. That is an honest way of saying it fits the existing hypothesis, and also that it is the same group building on its own prior work rather than an outside lab testing the claim independently.
Two further papers
A fourth paper looked at organotypic pineal cell culture rather than cortical or cerebellar neurons. Khavinson, Linkova, Chalisova and colleagues tested several bioregulator peptides on pinealocyte cultures from rat pineal glands and found that EDR did not affect the apoptosis marker AIF, unlike Epithalon's dipeptide relative Lys-Glu-Asp, which showed different signalling effects entirely.
That is a useful near-negative result. EDR is not doing everything every bioregulator peptide does, which cuts against treating these compounds as interchangeable and supports the tissue-specificity part of the framework (PMID 22803060).
A 2020 paper in Molecules revisited the DNA interaction hypothesis, proposing that EDR binding to gene promoter regions could influence specific protein synthesis pathways in neuronal cells (PMID 33396470). It is theoretical rather than new experimental data, but it shows the line of thinking is still active.
Research Considerations
Three practical points stand out for anyone designing work with this compound.
Stability. A tripeptide is small enough to cross membranes more readily than a larger peptide, and correspondingly more exposed to enzymatic degradation in solution. Verify peptide integrity under your own buffer and temperature conditions rather than assuming it.
Provenance. Almost all published work comes from one research group and independent replication is lacking. That does not invalidate the findings, but it does mean the literature should be read with caution and experiments designed to stand on their own.
Concentration. The 2011 concentration-response data shows different concentrations producing different cellular readouts, with two curves that saturate at different points. Concentration selection in vitro is not trivial here.
Researchers planning studies with Pinealon may find the peptide reconstitution calculator helpful for preparing accurate working solutions, and the stability calculator for assessing storage conditions. For those comparing Pinealon to other bioregulator peptides, the peptide glossary provides a useful reference for terminology.
Where the Evidence Leaves It
The published literature on Pinealon describes a synthetic tripeptide with three distinct lines of evidence: nuclear penetration and sequence-specific DNA binding in HeLa cells, ROS and cell-death readouts in cell culture and a prenatal stress animal model, and computational predictions of binding sites within the tryptophan hydroxylase gene. Each finding is interesting, but none has been independently replicated outside the originating group.
The "tissue-specific peptide bioregulator" framework remains a hypothesis, not established biology. For researchers, Pinealon represents a genuinely under-studied compound with a small but specific evidence base. The gap between the compound's published literature and its online visibility is real, and we hope this guide helps close it. For further reading on related compounds, see our BPC-157 research guide or browse the full catalog for laboratory research peptides.
Related Research Compounds
Every compound below is held to a >99% HPLC purity specification, which is a release threshold rather than a measurement. Published certificates for specific lots are listed on the certificates page, and a certificate for any other batch is available on request.
| Compound | Purity specification | Size |
|---|---|---|
| BPC-157 5mg | >99% | 5mg |
| BPC-157 10mg | >99% | 10mg |

